Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

@article{Zhang2020SafetyTA,
  title={Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial},
  author={Yanjun Zhang and Gang Zeng and Hongxing Pan and Changgui Li and Yaling Hu and Kai Chu and Weixiao Han and Zhen Chen and Rong Tang and Weidong Yin and Xin Chen and Yuansheng Hu and Xiaoyong Liu and Congbing Jiang and Jing-xin Li and Minnan Yang and Yan Song and Xiangxi Wang and Qiang Gao and Fengcai Zhu},
  journal={The Lancet. Infectious Diseases},
  year={2020},
  volume={21},
  pages={181 - 192}
}
  • Yanjun Zhang, G. Zeng, +17 authors Fengcai Zhu
  • Published 17 November 2020
  • Medicine
  • The Lancet. Infectious Diseases
Background With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability and immunogenicity. Methods In this randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, healthy… Expand
View on Elsevier
thelancet.com
341 Citations
Highly Influential Citations
10
Background Citations
50
Methods Citations
12
Results Citations
7

Figures and Tables from this paper

341 Citations

Citation Type

Citation Type

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
TLDR
A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial of CoronaVac in healthy adults aged 60 years and older in Renqiu (Hebei, China), finding that the vaccine is safe and well tolerated in older adults. Expand
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
  • B. Han, Yufei Song, +12 authors Q. Gao
  • Medicine
  • The Lancet Infectious Diseases
  • 2021
TLDR
A double-blind, randomised, controlled, phase 1/2 clinical trial of CoronaVac in healthy children and adolescents aged 3–17 years old at Hebei Provincial Center for Disease Control and Prevention in Zanhuang, China, finding most adverse reactions were mild and moderate in severity. Expand
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
TLDR
The safety and immunogenicity of the inactivated COVID-19 vaccine candidate BBIBP-CorV in participants aged 3–17 years were assessed and adverse reactions were mostly mild to moderate in severity. Expand
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
TLDR
The immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults in Chinese healthy adults is reported. Expand
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
TLDR
The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults and could be further evaluated for long-term safety and efficacy in the phase 3 trials. Expand
Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial
TLDR
Preliminary findings indicate that V-01 is safe and well tolerated, capable of inducing rapid and strong immune responses, and warrants further testing in phase Ⅱ/Ⅲ clinical trials. Expand
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
TLDR
CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile and is active but no longer recruiting. Expand
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to… Expand
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials
TLDR
Both doses of KCONVAC are well tolerated and able to induce robust immune responses in healthy adults and support testing 5-μg vaccine in the 0/28 regimen in an upcoming phase 3 efficacy trial. Expand
Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial
TLDR
Immunization with CoronaVac in a 0-14 schedule in adults of 18 years and older in the Chilean population is safe and induces specific IgG production against the S1-RBD with neutralizing capacity, as well as the activation of T cells secreting IFN-gamma upon recognition of SARS-CoV-2 antigens. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
TLDR
The primary outcomes were safety and tolerability and immunogenicity, assessed as the neutralising antibody responses against infectious SARS-CoV-2, and no serious adverse event was reported within 28 days post vaccination. Expand
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
TLDR
A dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain to assess the safety, tolerability, and immunogenicity. Expand
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
TLDR
In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Expand
Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
  • B. Hao, Z. Chen, +12 authors J. Huang
  • Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2019
TLDR
The varicella vaccine was effective in the prevention ofvaricella in children and an antibody titre of 1:8 was associated with protection against variceella. Expand
Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.
TLDR
The novel human EV71 inactivated vaccine was well tolerated and highly immunogenic in healthy volunteers, especially in infant populations, and for immune response, the seropositive rates of neutralizing antibody increased to 100% for all dosage groups after the second vaccination. Expand
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans. Expand
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine. Expand
SARS-CoV-2 vaccines in development
TLDR
The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans. Expand
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
TLDR
While further studies of SARS-CoV-2 are necessary to determine immune responses, evidence from other coronaviruses can provide clues and guide future research. Expand
Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
  • X. Wang, Xianghua Guo, +6 authors Quanyi Wang
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2020
TLDR
The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Expand
...
1
2
3
4
...